Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
EYPT Stock Summary
Top 10 Correlated ETFs
EYPT
In the News

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full-year 2022 financial results and highlight recent corporate developments.

5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
Analysts say these are penny stocks to buy. Do you agree?

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:13 AM ET EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q3 2022 Earnings Conference Call November 02, 2022, 08:30 AM ET Company Participants Nancy Lurker - President and CEO George Elston - CFO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen Yi Chen - H.C. Wainwright Yale Jen - Laidlaw & Company Daniil Gatualin - Chardan Yuan Zhi - B.

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022
WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments.

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Shares have lost 15% year to date. Durasert technology has been extensively validated and administered to over 80,000 patient eyes.

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and Chief Executive Officer Jay Duker - Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Jennifer Kim - Cantor Yale Jen - Laidlaw Yi Chen - H.C. Wainwright Operator Good morning.
EYPT Financial details
EYPT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-06-30 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.64 | 1.95 | 2.68 | 2.88 | 1.11 | |
Net income per share | -11.5 | -5.44 | -3.54 | -4.55 | -2.74 | |
Operating cash flow per share | -4.74 | -5.44 | -1.12 | -3.9 | -1.74 | |
Free cash flow per share | -4.76 | -5.46 | -1.15 | -3.92 | -1.8 | |
Cash per share | 8.39 | 2.13 | 3.5 | 16.48 | 3.87 | |
Book value per share | 2.53 | 0.8 | 1.44 | 14.36 | 2.58 | |
Tangible book value per share | -4.26 | -1.85 | -0.52 | 12.59 | 2.58 | |
Share holders equity per share | 2.53 | 0.8 | 1.44 | 14.36 | 2.58 | |
Interest debt per share | 3.9 | 5.44 | 3.71 | 3.48 | 1.31 | |
Market cap | 96.15M | 161.68M | 84.46M | 157.11M | 130.61M | |
Enterprise value | 74.68M | 190.06M | 79.86M | 17.72M | 80.75M | |
P/E ratio | -1.81 | -2.85 | -1.86 | -2.69 | -1.28 | |
Price to sales ratio | 32.47 | 7.94 | 2.45 | 4.25 | 3.15 | |
POCF ratio | -4.39 | -2.85 | -5.85 | -3.14 | -2.01 | |
PFCF ratio | -4.37 | -2.84 | -5.71 | -3.13 | -1.94 | |
P/B Ratio | 8.23 | 19.41 | 4.56 | 0.85 | 1.36 | |
PTB ratio | 8.23 | 19.41 | 4.56 | 0.85 | 1.36 | |
EV to sales | 25.22 | 9.33 | 2.32 | 0.48 | 1.95 | |
Enterprise value over EBITDA | -1.46 | -3.96 | -2.25 | -0.35 | -0.83 | |
EV to operating cash flow | -3.41 | -3.35 | -5.53 | -0.35 | -1.24 | |
EV to free cash flow | -3.39 | -3.34 | -5.4 | -0.35 | -1.2 | |
Earnings yield | -0.55 | -0.35 | -0.54 | -0.37 | -0.78 | |
Free cash flow yield | -0.23 | -0.35 | -0.18 | -0.32 | -0.51 | |
Debt to equity | 5.13 | 7.76 | 3.95 | 0.43 | 0.87 | |
Debt to assets | 0.84 | 0.89 | 0.8 | 0.3 | 0.47 | |
Net debt to EBITDA | 0.42 | -0.59 | 0.13 | 2.78 | 0.51 | |
Current ratio | 1.84 | 3.62 | 4.24 | 10.05 | 5 | |
Interest coverage | -36.49 | -7.75 | -5.14 | -10.05 | -31.24 | |
Income quality | 0.41 | 1 | 0.32 | 0.86 | 0.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.9 | 0.88 | 0.6 | 0.69 | 0.84 | |
Research and developement to revenue | 5.46 | 0.75 | 0.51 | 0.77 | 1.2 | |
Intangibles to total assets | 0.44 | 0.38 | 0.27 | 0.09 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.03 | 0 | 0.03 | |
Capex to revenue | -0.04 | -0.01 | -0.01 | 0 | -0.05 | |
Capex to depreciation | -0.09 | -0.08 | -0.14 | -0.06 | -1.05 | |
Stock based compensation to revenue | 0.91 | 0.22 | 0.16 | 0.2 | 0.34 | |
Graham number | 25.58 | 9.89 | 10.72 | 38.35 | 12.62 | |
ROIC | 2.98 | -1.97 | 12.81 | 0.55 | 5.92 | |
Return on tangible assets | -1.32 | -1.25 | -0.68 | -0.24 | -0.57 | |
Graham Net | -4.53 | -3.15 | -1.44 | 11.54 | 1.97 | |
Working capital | 18.25M | 30.2M | 48.23M | 214.09M | 138.27M | |
Tangible asset value | -19.67M | -19.34M | -6.67M | 161.63M | 96.37M | |
Net current asset value | -20.07M | -22.92M | -10.06M | 158.75M | 88.82M | |
Invested capital | 1.48 | 6.07 | 2.17 | 0.21 | 0.47 | |
Average receivables | 302K | 5.86M | 10.41M | 13.9M | 16.93M | |
Average payables | 1.98M | 3.57M | 4.5M | 6.1M | 6.65M | |
Average inventory | 0 | 1.07M | 3.74M | 4.48M | 3.25M | |
Days sales outstanding | 43.51 | 203.75 | 100.19 | 181.36 | 136.67 | |
Days payables outstanding | 0 | 569.44 | 301.51 | 329.65 | 259.48 | |
Days of inventory on hand | 0 | 290.42 | 334.48 | 161.41 | 126.52 | |
Receivables turnover | 8.39 | 1.79 | 3.64 | 2.01 | 2.67 | |
Payables turnover | 0 | 0.64 | 1.21 | 1.11 | 1.41 | |
Inventory turnover | 0 | 1.26 | 1.09 | 2.26 | 2.88 | |
ROE | -4.55 | -6.82 | -2.45 | -0.32 | -1.06 | |
Capex per share | -0.02 | -0.02 | -0.03 | -0.01 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.35 | 0.25 | 0.31 | 0.27 | 0.28 | |
Net income per share | -0.59 | -0.56 | -0.52 | -0.49 | -1.16 | |
Operating cash flow per share | -0.51 | -0.54 | -0.51 | -0.35 | -0.34 | |
Free cash flow per share | -0.51 | -0.55 | -0.52 | -0.38 | -0.35 | |
Cash per share | 6.47 | 5.12 | 4.59 | 4.21 | 3.87 | |
Book value per share | 5.64 | 4.48 | 4.06 | 3.65 | 2.58 | |
Tangible book value per share | 4.94 | 3.88 | 3.48 | 3.09 | 2.58 | |
Share holders equity per share | 5.64 | 4.48 | 4.06 | 3.65 | 2.58 | |
Interest debt per share | 1.24 | 1.14 | 1.21 | 1.26 | 1.25 | |
Market cap | 400.25M | 452.62M | 293.72M | 295.34M | 130.61M | |
Enterprise value | 260.86M | 392.36M | 256.07M | 266.44M | 80.75M | |
P/E ratio | -5.15 | -5.39 | -3.78 | -4.01 | -0.75 | |
Price to sales ratio | 34.67 | 48.7 | 25.4 | 29.5 | 12.4 | |
POCF ratio | -24.01 | -22.45 | -15.36 | -22.48 | -10.38 | |
PFCF ratio | -24.01 | -22.29 | -15.19 | -20.6 | -9.91 | |
P/B Ratio | 2.17 | 2.71 | 1.94 | 2.17 | 1.36 | |
PTB ratio | 2.17 | 2.71 | 1.94 | 2.17 | 1.36 | |
EV to sales | 22.6 | 42.22 | 22.14 | 26.61 | 7.67 | |
Enterprise value over EBITDA | -15.04 | -20.56 | -14.11 | -15.63 | -1.89 | |
EV to operating cash flow | -15.65 | -19.46 | -13.39 | -20.28 | -6.41 | |
EV to free cash flow | -15.65 | -19.32 | -13.24 | -18.59 | -6.13 | |
Earnings yield | -0.05 | -0.05 | -0.07 | -0.06 | -0.33 | |
Free cash flow yield | -0.04 | -0.04 | -0.07 | -0.05 | -0.1 | |
Debt to equity | 0.43 | 0.47 | 0.54 | 0.62 | 0.87 | |
Debt to assets | 0.3 | 0.32 | 0.35 | 0.38 | 0.47 | |
Net debt to EBITDA | 8.04 | 3.16 | 2.07 | 1.7 | 1.17 | |
Current ratio | 10.05 | 6.87 | 6.17 | 5.61 | 5 | |
Interest coverage | -13 | -15.31 | -34.81 | -27.79 | -56 | |
Income quality | 0.86 | 0.96 | 0.99 | 0.71 | 0.29 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.8 | 0.92 | 0.74 | 0.92 | 0.81 | |
Research and developement to revenue | 0.77 | 1.07 | 1.12 | 1.11 | 1.48 | |
Intangibles to total assets | 0.09 | 0.09 | 0.09 | 0.09 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0.01 | 0.09 | 0.05 | |
Capex to revenue | 0 | -0.02 | -0.02 | -0.12 | -0.06 | |
Capex to depreciation | 0 | -0.21 | -0.31 | -1.68 | 9.59 | |
Stock based compensation to revenue | 0.24 | 0.37 | 0.36 | 0.32 | 0.32 | |
Graham number | 8.68 | 7.53 | 6.89 | 6.37 | 8.23 | |
ROIC | 0.18 | -0.54 | -0.31 | -0.29 | 2.6 | |
Return on tangible assets | -0.08 | -0.09 | -0.09 | -0.09 | -0.24 | |
Graham Net | 4.53 | 3.47 | 2.88 | 2.42 | 1.97 | |
Working capital | 214.09M | 187.66M | 172.48M | 157.85M | 138.27M | |
Tangible asset value | 161.63M | 144.69M | 129.85M | 115.45M | 96.37M | |
Net current asset value | 158.75M | 141.89M | 123.8M | 107.96M | 88.82M | |
Invested capital | 0.21 | 0.25 | 0.29 | 0.34 | 0.47 | |
Average receivables | 15.98M | 18.97M | 21.09M | 21.74M | 18.19M | |
Average payables | 7.01M | 7.34M | 7.18M | 6.59M | 6.02M | |
Average inventory | 4.09M | 3.48M | 3.3M | 3.39M | 3.21M | |
Days sales outstanding | 143.09 | 189.69 | 175.83 | 187.66 | 132.47 | |
Days payables outstanding | 219.14 | 369.83 | 366.33 | 391.52 | 156.22 | |
Days of inventory on hand | 107.3 | 168.96 | 168.89 | 226.19 | 76.17 | |
Receivables turnover | 0.63 | 0.47 | 0.51 | 0.48 | 0.68 | |
Payables turnover | 0.41 | 0.24 | 0.25 | 0.23 | 0.58 | |
Inventory turnover | 0.84 | 0.53 | 0.53 | 0.4 | 1.18 | |
ROE | -0.11 | -0.13 | -0.13 | -0.14 | -0.45 | |
Capex per share | 0 | 0 | -0.01 | -0.03 | -0.02 |
EYPT Frequently Asked Questions
What is EyePoint Pharmaceuticals, Inc. stock symbol ?
EyePoint Pharmaceuticals, Inc. is a US stock , located in Watertown of Ma and trading under the symbol EYPT
Is EyePoint Pharmaceuticals, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $25. The lowest prediction is $25 and the highest is $25
What is EYPT stock prediction ?
What is EyePoint Pharmaceuticals, Inc. stock quote today ?
EyePoint Pharmaceuticals, Inc. stock price is $2.545 today.
Is EyePoint Pharmaceuticals, Inc. stock public?
Yes, EyePoint Pharmaceuticals, Inc. is a publicly traded company.